Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491. [electronic resource]
Producer: 20110824Description: 95; author reply 96-7 p. digitalISSN:- 1600-0609
No physical items for this record
Publication Type: Letter; Comment
There are no comments on this title.
Log in to your account to post a comment.